Search results
Results From The WOW.Com Content Network
Retinoblastoma (Rb) is a rare form of cancer that rapidly develops from the immature cells of a retina, [2] the light-detecting tissue of the eye. [3] It is the most common primary malignant intraocular cancer in children, and 80% of retinoblastoma cases are first detected in those under 3 years old.
In most cases trilateral retinoblastoma presents itself as pineoblastoma (pineal TRb). In about a fourth of the cases the tumor develops in another intracranial region, most commonly supra- or parasellar (non-pineal TRb), but there are reported cases with non-pineal TRb in the 3rd ventricle.
The retinoblastoma protein (protein name abbreviated Rb or pRb; gene name abbreviated Rb, RB or RB1) is a tumor suppressor protein that is dysfunctional in several major cancers. [5] One function of pRb is to prevent excessive cell growth by inhibiting cell cycle progression until a cell is ready to divide.
The protein encoded by this gene is similar in sequence and possibly function to the product of the retinoblastoma 1 gene.The RB1 gene product is a tumor suppressor protein that appears to be involved in cell cycle regulation, as it is phosphorylated in the S to M phase transition and is dephosphorylated in the G1 phase of the cell cycle.
In non-inherited retinoblastoma, instead two mutations, or "hits", had to take place before a tumor could develop, explaining the later onset. It was later found that carcinogenesis (the development of cancer) depended both on the mutation of proto-oncogenes (genes that stimulate cell proliferation ) and on the inactivation of tumor suppressor ...
The six million volt machine was first used for treatment in 1956, soon after the earliest linac-based radiation therapy, first used in London, England, in 1953. [1] The first patient treated by Kaplan was Gordon Isaacs, who suffered from retinoblastoma of his right eye, and the disease threatened his left eye. The patient survived into ...
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.
Current Medical Diagnosis and Treatment is a standard medical reference work [1] published by McGraw-Hill. It is updated annually and the current 2022 version is its 61st edition. [ 2 ] The editors of the 61st edition were Stephen McPhee, Maxine Papadakis, Michael Rabow and Kenneth McQuaid.